QVD-OPh, caspase inhibitor
Potent, cell-permeable, irreversible broad-spectrum caspase inhibitor
Potent, cell-permeable, irreversible broad-spectrum caspase inhibitor (IC50 values are 25, 50, 100 and 430 nM for caspase-3, 1, 8 and 9 respectively). Inhibits apoptosis. Shows anti-ischemic and neuroprotective effects in vivo. Blood-brain barrier permeable.
VD (Modifications: N-terminal quinolyl; C-terminal OPh)
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Soluble in DMSO to 100 mM
Q-VD-OPH is a novel, irreversible, pan caspase inhibitor specifically designed for in vivo and in vitro research. Q-VD-OPH is widely cited in the literature, and researchers should refer to the literature for additional information about the various species that Q-VD-OPH has been used for.For in vitro applications, Q-VD-OPH is typically used at final working concentration of 10-100 uM. The variability depends on model system, including cell type, culture, properties, and type of apoptosis induction treatments. Each researcher should empirically establish optimal working concentrations for their in vitro model system.
Human reactivity reported in scientific literature
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Form : Off-white Solid: Make a stock solution of 10 mM in high purity DMSO (>99.9%). Add 195 uL DMSO to 1 mg of the pan caspase inhibitor (Q-VD-OPH peptide) to make a 10 mM stock solution.
Members of the caspase family play key roles in apoptosis and inflammation. The OPH trap of Q-VD-OPH has superior potency, cell permeability, minimal toxicity, and provides an alternative to the fluoromethylketone (FMK) family of inhibitors. Like the FMK caspase inhibitors (reviewed in Thornberry and Lazebnik, 1998; Gregoli and Bondurant, 1999; Schrantz et al., 1999), Q-VD-OPH binds to the catalytic site of caspases proteases, and inhibits caspase-mediated apoptosis by preventing caspase activity. Users should consult the literature for additional information regarding applications for Q-VD-OPH (Caserta et al., 2003; Melnikov et al, 2002; Patil and Sharma, 2004)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Inhibitors are guaranteed for 1 year from date of receipt.
Q-VD-OPH is a cell permeable caspase peptide inhibitor. Caspase inhibitors irreversibly bind to the catalytic site of caspase proteases and inhibit apoptosis. Caspase inhibitors may be broad spectrum, inhibiting multiple caspases, or may preferentially inhibit particular caspases. Z-VAD-FMK, BOC-D-FMK, and Q-VD-OPH are examples of broad spectrum or pan caspase inhibitors. In contrast Z-DEVD-FMK preferentially inhibits caspases 3 and 7, Z-IETD-FMK preferentially inhibits caspase 8, Z-LEHD-FMK preferentiailly inhibits caspase 9. Z-FA-FMK is considered to be a negative control for FMK based caspase inhibitors.
Details of Functionality
Mass Spec: M+1=514.1
Chromatography: TLC:Rf: 0.4 Single Spot, EtOAC:6, ACOH:0.1
H NMR: All functional groups are present
Q-Val-Asp(non-omethylated)-OPH, also known as Q-VD(non-omethylated)-OPH. Molecular Weight: 513